Merck's Keytruda succeeds in late-stage lung cancer study

(Reuters) - Merck & Co on Wednesday said its cancer drug Keytruda helped extend survival and prevented disease progression when tested in a late-stage study in combination with chemotherapy for a type of lung cancer.